Comparison of Two Biodegradable Polymer Coated, Drug-Eluting Coronary Stents Paclitaxel vs. Sirolimus, with 6-Years Clinical Follow-Up: BIOPRESS (BIOdegradable Polymer REgistry Smt Stents) Infinnium vs. Supralimus

On which stent, sirolimus elution or paclitaxel elution is more effective in real-world controversy not selected

Patience Therefore, we examined the long-term safety and efficacy of paclitaxel-eluting stent (PES).

METHOD: Created potential customers, open tags, not random, multi-center registry and analysis data

Symptomatic coronary artery disease occurs in all patients in a continuous series

Through outpatient examination and telephone interview that can be divided into two groups depending on the type of stent, we reached 6 years old.

Annual clinical outcomes include death, myocardial infarction (MI), stent thrombosis (ST), acute lesion, and revascularization

(TLR), target vessel revascularization (TVR), and a major harmful car interactive response event (MACE, a combination of cardiac death)

Baseline clinical features and angiographic features were similar in both groups. Clinical follow-up for 6 years

529 patients (92.6%) were completed. Record a total of 4% of major harmful cardiac events in the hospital (MACE)

Supralimus® SES biodegradable polymer coated drug eluting stent (Sahajan and Medical Technologies Pvt.

This is an open access article licensed under Creative Commons Attribution, Non-Commercial Licensing Terms.

Each scaffold was coated with 1 μg of paclitaxel (percentage of paclitaxel in the polymer coating) per 1 mm 2 of scaffold surface area in 8.8% of the formulation. This is the same dose used in the commercial TAXUS® Express® 2 paclitaxel-eluting coronary stent system (P 030025) and the TAXUSO Libert® 60 paclitaxel-eluting coronary stent system (P 060008) Density and formulation. PtCr is selected as a scaffolding material due to its superior strength and radiopacity, allowing the scaffold to provide thinner struts with more flexible design due to better performance.

Biocompatibility data for API drugs, paclitaxel and SIB coatings were obtained for the coating process for the Taxus Liberte paclitaxel-eluting coronary stent system and the ION® paclitaxel-eluting platinum-chromium coronary stent system, . The coating amount is equivalent to Liberte stent and ION stent, unit area, total drug dose and unit area dose, and sterilization process. Stent (direct contact) of uncoated component with cytotoxicity (L929 MEM elution) / Part 5 cytotoxicity / uncoated component stent (maximum guinea pig) / part 10 coated No Component Holder Intradermal Reactive Passage / Part 10 Acute Systemic Toxicity of Uncoated Component Scaffold / Part 11 Uncoated Element Scaffold's Medium Medium Thermogenicity (Rabbit) / Part 11 Uncoated Element Scaffold from 14 Everyday Repeated dose venous toxicity / part 11 uncoated element stent passed

Porous scaffolds allow drug incorporation without the need for additional polymeric coatings that are common in drug eluting stents. Various surface modification techniques have been used to condition the surface to accommodate the drug for delivery. Long etching of the polymer surface can result in the formation of pores which can be used to hold drugs for topical delivery. The use of photolithography or soft lithography to produce porous microparticles or nanoparticles to create voids on the surface of polymer samples or to embed polymer surfaces for drug delivery is also under investigation. Sandblasting has been shown to effectively form porous surfaces on metal stents. The aluminum coating exposed to the acidic solution forms ceramic alumina, resulting in nanoscale pores on the membrane for drug delivery. Acid treatment of stainless steel stents also successfully produced porous surfaces for drug elution.

Review of surface modification technology for next-generation shape memory polymer scaffolds Tina Govindarajan and Robin Shandas *